Gilead Sciences, Inc. (NASDAQ:GILD) and Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Wednesday entered into an exclusive option and license agreement to accelerate the development and commercialization ...

A new Peter Mac study using a pioneering drug has successfully controlled the growth of tumors and overcome existing drug resistance in multiple cancer types. An enzyme critically associated with ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs—including a class of targeted ...

WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet ...

WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. today announced that its partner BeiGene has dosed the first five patients in its first-in-human Phase 1 trial to evaluate BG-68501, a small ...

Nikang Therapeutics Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 2 (CDK2) ...

CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and ...

CAMBRIDGE, Mass., May 23, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced updated data from the ongoing Phase 1 dose escalation portion of the VELA clinical trial ...

This preclinical study explains the mechanism underlying CDK2 and CDK4/6 combination therapy, providing a blueprint for future clinical use These findings are notable because several CDK2 inhibitor ...

Amid a flurry of dealmaking activity to start 2024, Allorion Therapeutics Inc., a 2020 startup based in Natick, Mass., and Guangzhou, China, has been extra busy. Two days after disclosing a potential ...